静脉利多卡因促进结肠手术肠道功能恢复:一项随机临床试验
ALLEGRO试验为随机、安慰剂对照、双盲研究,在英国27家医院纳入590例择期微创结肠切除患者,1:1随机接受2%静脉利多卡因(麻醉诱导时1.5 mg/kg负荷,继以1.5 mg/kg/h持续6或12小时)或0.9%生理盐水安慰剂。主要终点为术后72小时肠道功能恢复(GI-3复合终点:连续3餐耐受饮食且排气或排便),利多卡因组160例(57.3%)vs 安慰剂组164例(59.0%),校正绝对差-1.9%(95%CI -8.0%至4.2%),相对风险0.97(95%CI 0.88至1.07)。11项次要终点均无显著差异。结论:择期微创结肠切除术患者围术期给予2%静脉利多卡因未改善72小时肠道功能恢复。
要点
- 择期微创结肠切除患者围术期2%静脉利多卡因未提高72小时GI-3肠道功能恢复率:57.3% vs 59.0%,校正绝对差-1.9%(95%CI -8.0%至4.2%)。
- 利多卡因组与安慰剂组相对风险0.97(95%CI 0.88至1.07),未达统计学显著。
- 11项次要终点(包括GI-3恢复时间、GI-2恢复时间、术后肠梗阻、恶心呕吐评分、阿片消耗、QoR-15、生活质量等)均无显著差异。
- 给药方案为麻醉诱导时1.5 mg/kg负荷,继以1.5 mg/kg/h持续6或12小时,对照为0.9%生理盐水6或12小时。
- 该结果不支持将围术期静脉利多卡因用于加速择期微创结肠切除术后肠道功能恢复。
适用人群与场景
- 英国27家医院中计划行择期微创结肠切除术的成人患者,疾病为良性或恶性。
- 纳入时间为2018年8月13日至2023年4月11日,其中2020年3月20日至2020年7月6日暂停招募;末次随访为2023年8月10日。
诊断标准与关键阈值
- 主要终点GI-3复合终点:耐受饮食(连续3餐进食食物和饮料无显著恶心或呕吐)且排气或排便,评估时间为术后72小时。
- 次要终点GI-2:耐受口服饮食且排便。
处置流程与药物剂量
- 干预组:2%静脉利多卡因,麻醉诱导时给予1.5 mg/kg负荷量,继以1.5 mg/kg/h持续6或12小时。
- 对照组:0.9%生理盐水安慰剂持续6或12小时。
研究设计与关键结果
- ALLEGRO试验为随机、安慰剂对照、双盲试验,在英国27家医院纳入590例患者(利多卡因组295例,安慰剂组295例);随机后排除33例,最终分析557例(利多卡因组279例,安慰剂组278例;女性249例[44.7%];平均[SD]年龄66[10.9]岁);532例(96%)接受了随机治疗。
- 主要终点:术后72小时达到GI-3肠道功能恢复者,利多卡因组160例(57.3%)vs 安慰剂组164例(59.0%),校正绝对差-1.9%(95%CI -8.0%至4.2%),相对风险0.97(95%CI 0.88至1.07)。
- 11项次要终点(包括GI-3恢复时间、GI-2恢复时间、延长性术后肠梗阻、术后恶心呕吐评分、总体镇痛获益评分、术后阿片消耗、恢复质量-15、生活质量[EuroQol 5-Dimension 5-Level]、加速康复方案依从性、达到医学定义出院标准的时间、患者自评出院准备时间)在干预组与对照组之间均无显著差异。
证据类型、等级与局限
- 证据类型:随机、安慰剂对照、双盲临床试验(ALLEGRO试验)。
- 试验注册:isrctn.org Identifier: ISRCTN52352431。
- 局限:原文未报告局限性
对床旁实践的改变
- 择期微创结肠切除术患者围术期给予2%静脉利多卡因(1.5 mg/kg负荷,继以1.5 mg/kg/h持续6或12小时)未改善72小时肠道功能恢复,11项次要终点亦无显著差异。
- 原文结论未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Despite the recovery advantages of minimally invasive surgical techniques, delayed return of gut function after colectomy is a common barrier to timely discharge from hospital.
OBJECTIVE: To evaluate the effect of 2% perioperative intravenous lidocaine infusion on return of gut function after elective minimally invasive colon resection.
DESIGN, SETTING, AND PARTICIPANTS: The ALLEGRO trial was a randomized, placebo-controlled, double-blind trial conducted in 27 UK hospitals. A total of 590 adults scheduled for elective minimally invasive colon resection for benign or malignant disease were randomized 1:1 to 2% intravenous lidocaine or saline placebo. Enrollment occurred from August 13, 2018, to April 11, 2023, with a pause in recruitment from March 20, 2020, through July 6, 2020; final follow-up was on August 10, 2023.
INTERVENTIONS: The intervention patients received 2% intravenous lidocaine administered as 1.5-mg/kg bolus at induction of anesthesia followed by 1.5 mg/kg/h for 6 or 12 hours. Control patients received 0.9% saline placebo for 6 or 12 hours.
MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with return of gut function at 72 hours after surgery, defined by the GI-3 composite end point of tolerating diet (ingestion of food and drink without significant nausea or vomiting for 3 consecutive meals) and passage of flatus or stool. There were 11 secondary outcomes, including time to GI-3 recovery, time to GI-2 recovery (tolerance of oral diet and passage of stool), prolonged postoperative ileus, postoperative nausea and vomiting score, Overall Benefit of Analgesia Score, postoperative opioid consumption, Quality of Recovery-15, quality of life (EuroQol 5-Dimension 5-Level), enhanced recovery protocol adherence, time to meeting medically defined criteria for discharge, and time to patient self-assessed readiness for discharge.
RESULTS: The trial enrolled 590 patients (295 intervention, 295 control); after 33 postrandomization exclusions, 557 patients were included (279 intervention, 278 control; 249 female patients [44.7%]; mean [SD] age, 66 [10.9] years); 532 (96%) received the randomized treatment. Return of gut function as defined by the GI-3 composite outcome was achieved at 72 hours by 160 patients (57.3%) in the intravenous lidocaine group vs 164 patients (59.0%) in the placebo group (adjusted absolute difference, -1.9% [95% CI, -8.0% to 4.2%]; relative risk, 0.97 [95% CI, 0.88 to 1.07]). There was no significant difference between the intervention and control groups in any of the 11 secondary end points.
CONCLUSIONS AND RELEVANCE: Among patients undergoing elective minimally invasive colon resection, perioperative administration of 2% intravenous lidocaine did not improve return of gut function at 72 hours.
TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN52352431.
参考来源
- Paterson H, Vadiveloo T, Innes K, et al. Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery: A Randomized Clinical Trial. JAMA. 2025. PMID: 39602290. doi:10.1001/jama.2024.23898
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。